Moreover, it implies that combining inhibitors for both DYRK1A and DYRK1B could potentially offer a comprehensive approach to diabetes treatment, opening new avenues for targeted diabetes therapies that consider both β-cell proliferation and HGP. Here, SLC25A16 is linked to diabetes mellitus.